Join us   Log in  

PHARMASPIRE - Volume 14,Issue 2, 2022 , April-June

Pages: 90-96

Date of Publication: 23-Sep-2022

Print Article   Download XML  Download PDF

Recent advancements in nanoparticles drug delivery systems

Author: Yash Choudhary, Abhishek Verma, Galal Mohsen Hussein Alsayadi, Pallavi Sandal, Balak Das Kurmi

Category: Quality Assurance


Nanoparticles in drug-delivery systems are generated by a variety of research survey. Unique physicochemical characteristics of nanostructured biomaterials include their very small and structural adaptability, high surface area to mass ratio, high reactivity, and controlled size. It enables molecularly focused cancer treatment, targeted administration of early detection of cancer lesions, early detection of cancer lesions, imaging agents, and anticancer medications, identification of tumor molecular factors by non-invasive imaging. These characteristics may be used in medicine to get around some of the drawbacks of conventional treatments. They are employed in vivo to protect the drug entity in the systemic circulation, limit drug access to the targeted areas, and deliver the drug to the site of action at a regulated and sustained pace. It reduces adverse side effects and enables more effective drug use. It must be active and therapeutically effective while in circulation and present at the target location in the right amounts. We will now go through several elements of nanoparticle formulation, the impact of their properties, characterization, and the potential of nanomedicine, improving targeted delivery of therapeutic agents, applications in drug molecule delivery, the development of novel, more powerful diagnostic and screening techniques to expand the boundaries of molecular diagnostics, and difficulties in synthesis nanoparticle platforms for dispensing various drugs.

Keywords: Ceramic nanoparticles, Dendrimers, Liposomes, Microbes, Polymeric nanoparticles, Solid lipid nano particles

DOI: 10.56933/Pharmaspire.2022.14211



1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. 2020: p. 61-91.
2. Singh S, Pandey VK, Tewari RP, Agarwal V. Nanoparticle Choudhary, et al.: Recent advancement in nanoparticle drug delivery system 95 Pharmaspire | Vol. 14 | No. 2 | 2022based drug delivery system: Advantages and applications Indian J Sci Technol 2011;4:177-84.
3. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine 2005;1:22-30.
4. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761-9.
5. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Disco 2008;7:239-50.
6. Wang H, Zhou Y, Sun Q, Zhou C, Hu S, Lenahan C, et al. Update on nanoparticle-based drug delivery system for anti-inflammatory treatment. Front Bioeng Biotechnol 2021;9:630352.
7. Ahmad Z, Pandey Z, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: Formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci 2006;48:171-6.
8. Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002;64:1407-13.
9. Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010;148:359-67.
10. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009;38:185-96.
11. Urbán-Morlán Z, Ganem-Rondero A, Melgoza-Contreras LM, Escobar-Chávez JJ, Nava-Arzaluz MG, Quintanar-Guerrero D. Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method. Int J Nanomedicine 2010;5:611-20.
12. Schumacher I, Margalit R. Liposome-encapsulated ampicillin: Physicochemical and antibacterial properties.
J Pharm Sci 1997;86:635-41.
13. De Leo V, Milano F, Agostiano A, Catucci L. Recent advancements in polymer/liposome assembly for drug delivery: From surface modifications to hybrid vesicles. Polymers (Basel) 2021;13:1027.
14. Patil JS, Dhadde SB, Chandakavathe BN. Nanostructure drug delivery system is an option to solve antimicrobial drug resistance: Perspective review. In: Characterization and Biology of Nanomaterials for Drug Delivery. Amsterdam: Elsevier Inc; 2019. p. 165-97.
15. Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives. Int J Nanomedicine 2019;14:1937-52.
16. Jain KK. The Handbook of Nanomedicine. Vol. 404. Berlin: Springer; 2008.
17. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 2009;136:2-13.
18. Zieli?ska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules 2020;25:3731.
19. Souto EB, Almeida AJ, Müller RH. Lipid nanoparticles (SLN®, NLC®) for cutaneous drug delivery: Structure, protection and skin effects. J Biomed Nanotechnol 2007;3:317-31.
20. Bhatia T, Gupta GD, Kurmi BD, Singh D. Role of solid lipid nanoparticle for the delivery of lipophilic drugs and herbal medicines in the treatment of pulmonary hypertension. Pharm Nanotechnol 2022.
21. Kurmi BD, Gajbhiye V, Kayat J, Jain NK. Lactoferrinconjugated dendritic nanoconstructs for lung targeting of methotrexate. J Pharm Sci 2011;100:2311-20.
22. Tekchandani P, Kurmi BD, Paliwal R, Paliwal SR. Galactosylated TPGS micelles for docetaxel targeting to hepatic carcinoma: Development, characterization, and biodistribution study. AAPS PharmSciTech 2020;21:174.
23. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT. Dendrimer-silver complexes and nanocomposites as antimicrobial agents. Nano Lett 2001;1:18-21.
24. Devarakonda B, Hill RA, Liebenberg W, Brits M, De Villiers MM. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm 2005;304:193-209.
25. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2012;64:102-15.
26. Moreno-Vega AI, Gómez-Quintero T, Nuñez-Anita RE, Acosta-Torres LS, Castaño V. Polymeric and ceramic nanoparticles in biomedical applications 2012. J Nanotechnol 2012;2021:936041.
27. Fadeel B, Garcia-Bennett AE. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 2010;62:362-74.
28. Thomas SC, Mishra PK, Talegaonkar SJ. Ceramic nanoparticles: Fabrication methods and applications in drug delivery. Curr Pharm Des 2015;21:6165-88.
29. Yih T, Al-Fandi MJ. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 2006;97:1184-90.
30. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71-7.
31. Pandey R, Sharma S, Khuller Gk. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv 2006;13:287-94.
32. Sanna V, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical deliveryof econazole nitrate: In-vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol 2007;59:1057-64.
33. Ranghar S, Sirohi P, Verma P, Agarwal V. Nanoparticlebased drug delivery systems: Promising approaches against infections. Brazillian Arch Biol Technol 2014;57:209-22.
34. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release Choudhary, et al.: Recent advancement in nanoparticle drug delivery system Pharmaspire | Vol. 14 | No. 2 | 2022 96 and delivery, pharmacokinetics and biocompatibility. J Mater Chem 2011;21:5845-55.
35. Yang J, Lee J, Kang J, Lee K, Suh JS, Yoon HG, et al. Hollow silica nanocontainers as drug delivery vehicles. Langmuir 2008;24:3417-21.
36. Patel P, Wahan SK, Vishakha S, Kurmi BD, Gupta GS, Rajak H, et al. Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent. Curr Cancer Drug Targets 2022.
37. Kurmi BD, Tekchandani P, Paliwal R, Paliwal SR. Nanocarriers in improved heparin delivery: Recent updates. Curr Pharm Des 2015;21:4509-18.
38. Kurmi BD, Paliwal SR. Development and optimization of TPGS-based stealth liposome of doxorubicin using BoxBehnken design: Characterization, hemocompatibility, and cytotoxicity evaluation in breast cancer cells. J Liposome Res 2022;32:129-45.
39. Kurmi BD, Paliwal R, Paliwal SR. Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: A quality by design approach. Int J Biol Macromol 2020;164:2881-94.
40. Tekchandani P, Kurmi BD, Paliwal SR. Nanomedicine to deal with cancer cell biology in multi-drug resistance. Mini Rev Med Chem 2017;17:1793-810